Even though, the number of potential HTX recipients has increased by 50% since 200415, the number of donors has remained almost unchanged. Nevertheless, donors are regularly excluded from heart donation because of the limited preservation time to reach a suitable recipient.1 Improving the utilization rate of grafts is therefore an important goal in transplant surgery.
Ex vivo perfusion systems are one of the strategies which have been developed as solution. Oxygenated blood is used to perfuse the graft and hereby to reduce graft damage. Besides isolated case reports describing a conservation time of 8h [Heartbeat device 16] to 10h [OCS by TransMedics 17], reliable clinically relevant studies are still missing. As limiting factor activated blood and the further release of metabolic agents from the graft lead to cardiac edema and inflammation as a sign of myocardial impairment.18 Additionally, in terms of practicability several issues must be considered: Present ex vivo perfusion systems require special equipment and training of surgeons and technicians, which results in considerably higher costs. Therefore, this organ procurement procedure may not be feasible for all hospitals.
Based on these limitations we aimed on an improvement strategy of the well-established Custodiol solution.4-6,19-22 The primary target of our work was to further reduce myocardial damage during standard conservation times of 4h and secondary to point out an opportunity to safely reach prolonged organ preservation without the need of specialized staff or expensive equipment.
Indeed, the comparison of Custodiol to Custodiol-N in a 4h ischemia/reperfusion setup (series 1, figure 2 and 3) showed that also in routine cardiac surgery with ischemic times of 4h and less Custodiol-N could have an implication, which is indicated by a significant improvement of load independent contractility parameters – such as ESPVR and PRSW (Figure 2). Remarkably, the contractility was recovered almost to baseline levels in this setup.
Also the secondary goal, which was to titrate the absolute borders of Custodiol-N, showed remarkable results: In series 2, long ischemic times of 8h, 12h and 16h were evaluated. All Custodiol groups had macroscopic signs of severe ischemic injury in series 2. None of the animals could be weaned from cardiopulmonary bypass, not even under inotropic support. In contrast, almost all animals from the Custodiol-N group could be weaned from the heart lung machine and were hemodynamically stable under inotropic support.
Improved vascular function, and thereby improved CBF, can contribute to better cardiac performance and better graft outcome.(35) This improvement was already seen as secondary findings in series 1, and it was confirmed during extended ischemic conservation periods in series 2. Again, to find the absolute limitations of Custodiol-N we investigated 24h ischemic conservation time and found only a significant impairment in the Custodiol group but not in the Custodiol-N group.
Several mechanisms behind these protective effects of Custodiol-N have already been described by our previous studies: Some of the agents used in Custodiol have been replaced by further developed substances. One of these is histidine, which on one hand is an excellent buffer but on the other also contributes to cell toxicity.7 It was partly replaced by N-α-acetyl-L-histidine, which shares similar capabilities but has a reduced cellular uptake.6,7,13,20 Furthermore the membrane stabilizing amino acids glycine and alanine have been added to Custodiol-N.6,7,20,23 Beside these well described mechanisms we were able to explore and prove the key mechanisms of Custodiol-N:
It is known that myocardial dysfunction and impairment of force are directly linked to sarcomere function.24,25 Sarcomere function itself is dependent to its sensitivity to Ca2+, which again can be altered by hyper- or hypo-phosphorilation. This sensitive balance between proteinkinase A, which indirectly increases the phosphorylation of sacromeric proteins, and proteinkinase C, which has contrary effects, is influenced by ischemia/reperfusion injury.26 In consequence an in- as well as a de-creased Ca2+ sensitivity indicates a dysregulated phosphorylation of sacromeric proteins and hereby a severe damage to the myocardial tissue. Our in vitro measurements of myocardial sacromeres Ca2+ sensitivity, showed a significantly decrease compared to native controls.(Figure 6) Custodiol-N preserved this balanced complex system and thereby myocardial function.
Beside these known mechanistic insides, we now focused on the generation of reactive oxygen species (ROS) by the Fenton reaction as key mechanism.12,20 The Fenton reaction is boosted by chelatable iron.7,12 Two different types of iron chelators were introduced, deferoxamine and LK614 [1-(N-hydroxy-N-methylcarbamide)-3,4-dimethoxybenzol], to address this topic. LK614 is smaller and more lipophilic than deferoxamine, which allows membrane permeability.7,20,27 Indeed, for the first time we proved a reduction of chelateable iron content in vivo using a exclusively developed assay.(Figure 8) Together with our previous work, in which we showed a significant reduction of myocardial apoptosis,7 the present results gives us an impression of the link between iron chelators, reduction of iron content and hereby also of apoptosis and finally preservation of myocardial function.
In the past, also other pharmacologic approaches have been made to improve pre-existing cardioplegic solutions for prolonged ischemic storages: Baxter and collegues demonstrated the conservation of rat hearts for 16h using Wisconsin solution supplemented by nitroglycerine.28 Kevelaitis et al suggested the Na+/H+ exchange inhibitor cariporide as well as the mitochondrial KATP channel (mitoKATP) agonist diazoxide in a rat model as additive to Celsior solution for prolonged storage.29 Similar results were seen for BMS-180448 - another mitoKATP agonist - in a rat working heart model.30 However, none of these approaches could be advanced to a clinical trial. In contrast to that, our findings were conducted in this clinically relevant canine model and suggested a safety margin between 12h and 16h. These results encouraged us to conduct a presently ongoing clinical trial using.
Summarizing, Custodiol-N has superior protection abilities compared to Custodiol at standard ischemic times. Unlike alternative approaches such as the ex vivo organ perfusion, Custodiol-N can be used very cost efficiently. Additionally, the results are promising for extended ischemic conservation periods. The mechanisms behind these effects are linked to a stabilization of Ca2+ sensitivity on sarcomere level and on the reduction of the chelateable iron pool. Therefore, our present approach for organ conservation may be an improvement in cardiac surgery.
Limitations:
The following limitations of this study must be addressed. To finally transfer these results to patients, additional, clinical studies must be performed. Additionally, further experimental are required to test the exact safety boundaries of Custodiol-N regarding extended ischemic conservation.